Newsfeeds - Spark Newswire

5 minute read

Reported Late Tuesday March 14, Deciphera Pharmaceuticals Announces QINLOCK Included In NCCN Guidelines For The Treatment Of Second-Line GIST Patients And FDA Grants Breakthrough Therapy Designation For QINLOCK In Second-Line GIST Patients With Mutatio…

By Happy Mohamed

Today, 8:27 PM

– NCCN Guidelines Include QINLOCK as a Preferred Regimen for Second-Line GIST Patients Intolerant to Sunitinib –

DCPH

1 minute read

HC Wainwright & Co. Reiterates Buy on Deciphera Pharmaceuticals, Maintains $25 Price Target

By Benzinga Newsdesk

Today, 8:27 PM

HC Wainwright & Co. analyst Andrew Fein reiterates Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy and maintains $25 price target.

DCPH

1 minute read

SVB Leerink Reiterates Outperform on Deciphera Pharmaceuticals, Maintains $30 Price Target

By Benzinga Newsdesk

Today, 8:27 PM

SVB Leerink analyst Andrew Berens reiterates Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Outperform and maintains $30 price target.

DCPH

1 minute read

SVB Leerink Maintains Outperform on Deciphera Pharmaceuticals, Raises Price Target to $30

By Benzinga Newsdesk

Today, 8:27 PM

SVB Leerink analyst Andrew Berens maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Outperform and raises the price target from $28 to $30.

DCPH

9 minute read

Earnings

Earnings Scheduled For February 7, 2023

By Benzinga Insights

Today, 8:27 PM

Companies Reporting Before The Bell • BP (NYSE:BP) is likely to report quarterly earnings at $1.67 per share on revenue of $53.79 billion.

AAT

2 minute read

$30M Bet On Deciphera Pharmaceuticals? Check Out These 4 Stocks Insiders Are Buying

By Lisa Levin

Today, 8:27 PM

Although US stocks closed mixed on Tuesday, there were a few notable insider trades.

APPN

2 minute read

Deciphera Pharmaceuticals Announces Pricing Of $125M Public Offering Of 6,944,445 Shares Of Common Stock At A Price Of $18/Share

By Benzinga Newsdesk

Today, 8:27 PM

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the

DCPH

4 minute read

Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session

By Lisa Levin

Today, 8:27 PM

Gainers Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of special dividend and appointed Timothy Murphy to lead Illegal Trading Task Force.

ACGN